Brian Roberts appointed as Chief Financial Officer by Tarveda Therapeutics

Clinical stage biopharmaceutical company into discovering and developing Pentarins which is a new class of potent and selective cancer medicines announced the appointment of Brian Roberts, a former Chief financial and operating officer at Avedro as its new Chief Financial officer who has an experience of 25 years n the field of finance, capital markets and operations. His expertise spans from life sciences to medtech and media industries where he has exhibited exemplary skills and leadership for financing companies and driving shareholder values thus signifying commendable growth for the companies he has served till date.

Drew Fromkin, President and Chief Executive Officer of Tarveda , said “Brian brings a unique balance of deep healthcare industry experience in pre- and post-revenue as well as private and public companies coupled with proven financial and operating expertise. His breadth of abilities and experiences make him the ideal choice to help guide Tarveda toward our business and financial objectives as we enter our next phase of growth.”

During his stint at Avedro, he led the company to several milestones like seeking FDA approval, manufacturing readiness and commercial launch of its lead combination drug. Previously, he served as Chief Financial Officer (CFO) at Insulet Corporation, a leader in tubeless insulin pump technology. He ensured that Insulet witnesses significant growth 30 million to nearly $300 million in revenue. His other noteworthy stints include Jingle Networks, mobile voice-ad services, Digitas, Idiom technologies and Ernst and Young LLP.